Sept 20, 2017 – Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of an $8 million equity financing round at a valuation of approximately $50 Million pre-closing. Korea Investment Partners (KIP) has invested USD 6 million in the financing round, and Hadasit Bio Holdingings Ltd. (HBL) (TASE:HDST) has co-invested USD 2 million.

More on Enlivex Therapeutics Ltd.:

For more information, see:-